Patents by Inventor Wafik S. El-Deiry

Wafik S. El-Deiry has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MIR-3132 UPREGULATION OF THE TRAIL PATHWAY AND APOPTOTIC ACTIVITY IN CANCER CELLS
    Publication number: 20210254060
    Abstract: The present disclosure provides compositions comprising miR-3132 and one or more pharmaceutical agents that upregulate TNF-related apoptosis-inducing ligand (TRAIL) or activate TRAIL signaling pathway, and methods for treating a cancer comprising administering miR-3132, or a composition comprising miR-3132 and one or more pharmaceutical agents that upregulate TRAIL or activate TRAIL signaling pathway, to a subject.
    Type: Application
    Filed: March 11, 2019
    Publication date: August 19, 2021
    Inventors: Amriti R. Lulla, Wafik S. El-Deiry
  • Treatment of tumors with miRNA targeting CDK4/CDK6
    Patent number: 11034959
    Abstract: The present disclosure provides miRNA mimics targeting CDK4 and/or CDK6, and compositions comprising the same. Methods for the treatment of tumors, including but not limited to colon cancer, comprising administering a modified oligonucleotide comprising a miRNA are also disclosed herein.
    Type: Grant
    Filed: February 26, 2018
    Date of Patent: June 15, 2021
    Assignee: Institute For Cancer Research
    Inventors: Amriti R. Lulla, Wafik S. El-Deiry
  • Prodigiosin Analogs And Methods Of Use
    Publication number: 20210139465
    Abstract: Prodigiosin analogs which reactivate the p53 pathway are provided, as well as compositions of these compounds, and methods for reactivation of the p53 pathway using these compounds are provided. The prodigiosin analogs may be used to treat cancer in which p53 mutation plays a role, including prostate cancer, breast cancer, kidney cancer, ovarian cancer, lymphoma, leukemia, and glioblastoma, among others.
    Type: Application
    Filed: October 21, 2020
    Publication date: May 13, 2021
    Inventors: Wafik S. El-Deiry, Xiaobing Tian
  • Dual inhibition of CDK and HSP90 destabilize H1F1 ? and synergistically induces cancer cell death
    Patent number: 10987356
    Abstract: The present disclosure provides pharmaceutical compositions including a CDK inhibitor and an HSP90 inhibitor, as well as methods of treating cancer or a tumor in a subject by administering a CDK inhibitor and an HSP90 inhibitor to the subject.
    Type: Grant
    Filed: November 12, 2019
    Date of Patent: April 27, 2021
    Assignee: Institute For Cancer Research
    Inventors: Shuai Zhao, Wafik S. El-Deiry
  • FREQUENT EGFR AND NTRK SOMATIC MUTATIONS IN COLORECTAL CANCER (CRC) WITH MICROSATELLITE INSTABILITY (MSI)
    Publication number: 20210054463
    Abstract: The present disclosure provides methods for identifying subjects having a cancer or tumor that may be susceptible to treatment with a therapeutic agent used to EGFR-related cancer an/or NTRK-related cancer.
    Type: Application
    Filed: February 26, 2018
    Publication date: February 25, 2021
    Inventors: Safoora Deihimi, Michael Slifker, Wafik S. El-Deiry
  • Prodigiosin analogs and methods of use
    Patent number: 10870640
    Abstract: Prodigiosin analogs which reactivate the p53 pathway are provided, as well as compositions of these compounds, and methods for reactivation of the p53 pathway using these compounds are provided. The prodigiosin analogs may be used to treat cancer in which p53 mutation plays a role, including prostate cancer, breast cancer, kidney cancer, ovarian cancer, lymphoma, leukemia, and glioblastoma, among others.
    Type: Grant
    Filed: April 27, 2019
    Date of Patent: December 22, 2020
    Assignee: Institute For Cancer Research
    Inventors: Wafik S. El-Deiry, Xiaobing Tian
  • Compound for anti-cancer therapy that acts by targeting GOF mutant p53 and stimulates p73 to restore the p53 pathway signaling
    Patent number: 10744133
    Abstract: The invention includes compositions comprising NSC59984 or a derivative or analogue thereof and a pharmaceutically acceptable carrier. The invention further includes methods of treating or preventing cancer in a subject, comprising the step of administering to the subject the compositions contemplated within the invention.
    Type: Grant
    Filed: April 29, 2019
    Date of Patent: August 18, 2020
    Assignee: The Penn State Research Foundation
    Inventors: Wafik S. El-Deiry, Shengliang Zhang
  • Dual inhibition of CDK and HSP90 destabilize HIF1alpha and synergistically induces cancer cell death
    Patent number: 10729692
    Abstract: The present disclosure provides pharmaceutical compositions including a CDK inhibitor and an HSP90 inhibitor, as well as methods of treating cancer or a tumor in a subject by administering a CDK inhibitor and an HSP90 inhibitor to the subject.
    Type: Grant
    Filed: February 26, 2018
    Date of Patent: August 4, 2020
    Assignee: Institute For Cancer Research
    Inventors: Shuai Zhao, Wafik S. El-Deiry
  • Dual Inhibition Of CDK And HSP90 Destabilize H1F1alpha And Synergistically Induces Cancer Cell Death
    Publication number: 20200155554
    Abstract: The present disclosure provides pharmaceutical compositions including a CDK inhibitor and an HSP90 inhibitor, as well as methods of treating cancer or a tumor in a subject by administering a CDK inhibitor and an HSP90 inhibitor to the subject.
    Type: Application
    Filed: November 12, 2019
    Publication date: May 21, 2020
    Inventors: Shuai Zhao, Wafik S. El-Deiry
  • Prodigiosin analogs
    Patent number: 10654801
    Abstract: Prodigiosin analogs which reactivate the p53 pathway are provided, as well as compositions of these compounds, and methods for reactivation of the p53 pathway using these compounds are provided. The prodigiosin analogs may be used to treat cancer in which p53 mutation plays a role, including prostate cancer, breast cancer, kidney cancer, ovarian cancer, lymphoma, leukemia, and glioblastoma, among others.
    Type: Grant
    Filed: April 10, 2017
    Date of Patent: May 19, 2020
    Assignee: Institute For Cancer Research
    Inventors: Wafik S. El-Deiry, Xiaobing Tian, Shengliang Zhang
  • TREATMENT OF TUMORS WITH MIRNA TARGETING CDK4/CDK6
    Publication number: 20200056184
    Abstract: The present disclosure provides miRNA mimics targeting CDK4 and/or CDK6, and compositions comprising the same. Methods for the treatment of tumors, including but not limited to colon cancer, comprising administering a modified oligonucleotide comprising a miRNA are also disclosed herein.
    Type: Application
    Filed: February 26, 2018
    Publication date: February 20, 2020
    Inventors: Amriti R. Lulla, Wafik S. El-Deiry
  • Prodigiosin Analogs And Methods Of Use
    Publication number: 20190375731
    Abstract: Prodigiosin analogs which reactivate the p53 pathway are provided, as well as compositions of these compounds, and methods for reactivation of the p53 pathway using these compounds are provided. The prodigiosin analogs may be used to treat cancer in which p53 mutation plays a role, including prostate cancer, breast cancer, kidney cancer, ovarian cancer, lymphoma, leukemia, and glioblastoma, among others.
    Type: Application
    Filed: April 27, 2019
    Publication date: December 12, 2019
    Inventors: Wafik S. El-Deiry, Xiaobing Tian
  • Compound For Anti-Cancer Therapy That Acts By Targeting GOF Mutant P53 And Stimulates P73 To Restore The P53 Pathway Signaling
    Publication number: 20190247391
    Abstract: The invention includes compositions comprising NSC59984 or a derivative or analogue thereof and a pharmaceutically acceptable carrier. The invention further includes methods of treating or preventing cancer in a subject, comprising the step of administering to the subject the compositions contemplated within the invention.
    Type: Application
    Filed: April 29, 2019
    Publication date: August 15, 2019
    Inventors: Wafik S. El-Deiry, Shengliang Zhang
  • Compounds For Repressing Cancer Cell Growth
    Publication number: 20190225613
    Abstract: The disclosure generally relates to compounds, compositions, and methods for the treatment of cancer by restoring the P53 pathway signaling to repress cancer cell growth.
    Type: Application
    Filed: January 23, 2019
    Publication date: July 25, 2019
    Inventors: Wafik S. El-Deiry, Shengliang Zhang, Liz J. Hernandez Borrero
  • Compound for anti-cancer therapy that acts by targeting GOF mutant P53 and stimulates P73 to restore the P53 pathway signaling
    Patent number: 10322123
    Abstract: The invention includes compositions comprising NSC59984 or a derivative or analog thereof and a pharmaceutically acceptable carrier. The invention further includes methods of treating or preventing cancer in a subject, comprising the step of administering to the subject the compositions contemplated within the invention.
    Type: Grant
    Filed: September 29, 2015
    Date of Patent: June 18, 2019
    Assignee: THE PENN STATE RESEARCH FOUNDATION
    Inventors: Wafik S. El-Deiry, Shengliang Zhang
  • Prodigiosin Analogs
    Publication number: 20190119207
    Abstract: Prodigiosin analogs which reactivate the p53 pathway are provided, as well as compositions of these compounds, and methods for reactivation of the p53 pathway using these compounds are provided. The prodigiosin analogs may be used to treat cancer in which p53 mutation plays a role, including prostate cancer, breast cancer, kidney cancer, ovarian cancer, lymphoma, leukemia, and glioblastoma, among others.
    Type: Application
    Filed: April 10, 2017
    Publication date: April 25, 2019
    Inventors: Wafik S. El-Deiry, Xiaobing Tian, Shengliang Zhang
  • Dual Inhibition Of CDK And HSP90 Destabilize HIF1alpha And Synergistically Induces Cancer Cell Death
    Publication number: 20180243306
    Abstract: The present disclosure provides pharmaceutical compositions including a CDK inhibitor and an HSP90 inhibitor, as well as methods of treating cancer or a tumor in a subject by administering a CDK inhibitor and an HSP90 inhibitor to the subject.
    Type: Application
    Filed: February 26, 2018
    Publication date: August 30, 2018
    Inventors: Shuai Zhao, Wafik S. El-Deiry
  • SMALL MOLECULE TRAIL GENE INDUCTION BY NORMAL AND TUMOR CELLS AS AN ANTICANCER THERAPY AND TUMOR CELLS AS AN ANTICANCER THERAPY
    Publication number: 20170224690
    Abstract: Methods and compositions relating to TIC10 are described according to aspects of the present invention. The compositions and methods have utility in treating disease, particularly cancer in a subject in need thereof, including a human subject as well as subjects of other species. The compositions have utility in treating brain cancer in a subject in need thereof.
    Type: Application
    Filed: April 23, 2017
    Publication date: August 10, 2017
    Applicant: The Penn State Research Foundation
    Inventors: Joshua E. ALLEN, Gen Sheng WU, Wafik S. EL-DEIRY
  • A Compound For Anti-Cancer Therapy That Acts By Targeting GOF Mutant P53 And Stimulates P73 To Restore The P53 Pathway Signaling
    Publication number: 20170209438
    Abstract: The invention includes compositions comprising NSC59984 or a derivative or analogue thereof and a pharmaceutically acceptable carrier. The invention further includes methods of treating or preventing cancer in a subject, comprising the step of administering to the subject the compositions contemplated within the invention.
    Type: Application
    Filed: September 29, 2015
    Publication date: July 27, 2017
    Inventors: Wafik S. El-Deiry, Shengliang Zhang
  • Small molecule TRAIL gene induction by normal and tumor cells as an anticancer therapy
    Patent number: 9629842
    Abstract: Methods and compositions relating to TIC10 are described according to aspects of the present invention. The compositions and methods have utility in treating disease, particularly cancer in a subject in need thereof, including a human subject as well as subjects of other species. The compositions have utility in treating brain cancer in a subject in need thereof.
    Type: Grant
    Filed: September 19, 2016
    Date of Patent: April 25, 2017
    Assignee: THE PENN STATE RESEARCH FOUNDATION
    Inventors: Wafik S. El-Deiry, Joshua E. Allen, Gen Sheng Wu